Demyelinating diseases
Education on Demyelinating diseases and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Demyelinating diseases and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Demyelinating diseases?
Demyelinating diseases is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Neurological conditions affect the brain, spinal cord, or nerves. The patent explores links between AAT levels and certain neurodegenerative processes.
What Mark Egly's patent discusses
A demyelinating disease is any condition that results in damage to myelin sheath, which is the protective covering that surrounds nerve fibers in the brain, optic nerves, and spinal cord. When the myelin sheath is damaged, nerve impulses slow or even stop, causing neurological problems. Demyelinating diseases include multiple sclerosis, optic neuritis, neuromyelitis optica, transverse myelitis, adrenoleukodystrophy, adrenomyeloneuropathy, and other conditions. Demyelination is a factor in dementia and Alzheimer's disease. The blood brain barrier can be infiltrated when NE is uninhibited. Nerve fibers can suffer degradation from excess neutrophil elastase damaging nerve cells. Multiple sclerosis ("MS") is the most common demyelinating disease of the central nervous system. MS is an unpredictable disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. MS involves an immune-mediated process in which an abnormal response of the body's immune system is directed against the central nervous system. Within the central nervous system, the immune system causes inflammation that damages myelin, which is the fatty substance…
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Demyelinating diseases, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Demyelinating diseases, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: